Science Simplified: Differences Between a Gene Therapy Clinical Trial and a Cure
source: pixabay.com

Science Simplified: Differences Between a Gene Therapy Clinical Trial and a Cure

Want to learn about scientific topics without needing a PhD? Check out the Science Simplified blog from TESS Research Foundation! Dr. Tanya Brown, PhD, works with researchers to make science…

Continue Reading Science Simplified: Differences Between a Gene Therapy Clinical Trial and a Cure
Gene Therapy Led to “Robust Microdystrophin Expression” in Duchenne Muscular Dystrophy Patient
source: pixabay.com

Gene Therapy Led to “Robust Microdystrophin Expression” in Duchenne Muscular Dystrophy Patient

Duchenne muscular dystrophy (DMD) is an inherited disease that weakens a child’s muscles and eventually spreads throughout the child’s body. DMD is caused by mutations in the gene that helps…

Continue Reading Gene Therapy Led to “Robust Microdystrophin Expression” in Duchenne Muscular Dystrophy Patient
FDA Approves Gene Therapy Lenmeldy for Metachromatic Leukodystrophy (MLD)
source: pixabay.com

FDA Approves Gene Therapy Lenmeldy for Metachromatic Leukodystrophy (MLD)

A majority of available treatment options for metachromatic leukodystrophy (MLD) rely on relieving symptoms. However, the recent approval of Lenmeldy (atidarsagene autotemcel) is the first ever FDA-approved gene therapy option…

Continue Reading FDA Approves Gene Therapy Lenmeldy for Metachromatic Leukodystrophy (MLD)
Experimental Gene Therapy Showed Promising Safety and Efficacy in Primate Study of Late-Infantile Batten Disease
source: shutterstock.com

Experimental Gene Therapy Showed Promising Safety and Efficacy in Primate Study of Late-Infantile Batten Disease

Children with late-infantile onset Batten disease (CLN2) may be treated with an enzyme replacement therapy (ERT). However, this therapy cannot reverse the damage or progression children have already experienced. Researchers…

Continue Reading Experimental Gene Therapy Showed Promising Safety and Efficacy in Primate Study of Late-Infantile Batten Disease
Wave Life Science’s New Trial Application is Causing Renewed Excitement Around RNA Editing
source: shutterstock.com

Wave Life Science’s New Trial Application is Causing Renewed Excitement Around RNA Editing

  If Wave Life Sciences’ recently submitted trial application for WVE-006 is approved, it will become the first RNA editing treatment in a clinical development setting. Wave’s CEO, Paul Bolno,…

Continue Reading Wave Life Science’s New Trial Application is Causing Renewed Excitement Around RNA Editing
Death of Muscular Dystrophy Patient Potentially Caused by Adeno-Associated Virus That Delivered Gene Therapy
source: pixabay.com

Death of Muscular Dystrophy Patient Potentially Caused by Adeno-Associated Virus That Delivered Gene Therapy

For over four decades, the aspiration of gene therapy has been to develop novel therapies with the potential to enhance human health. Recombinant AAV (rAAV), a type of gene therapy,…

Continue Reading Death of Muscular Dystrophy Patient Potentially Caused by Adeno-Associated Virus That Delivered Gene Therapy
Researchers Track Gene Therapy’s Impact on Neural Connections in Hurler Syndrome
source: shutterstock.com

Researchers Track Gene Therapy’s Impact on Neural Connections in Hurler Syndrome

617 words (source - 3% match) vs. 452 words (mine - 4% match) As our healthcare field continues to innovate and grow, we have seen more conversations regarding gene therapy…

Continue Reading Researchers Track Gene Therapy’s Impact on Neural Connections in Hurler Syndrome
A Top FDA Official Overrules Reviewers’ Rejection of Sarepta’s DMD Gene Therapy
source: shutterstock.com

A Top FDA Official Overrules Reviewers’ Rejection of Sarepta’s DMD Gene Therapy

  It looked as if the fate of Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy was pretty much sealed until an FDA official intervened. This information was provided by…

Continue Reading A Top FDA Official Overrules Reviewers’ Rejection of Sarepta’s DMD Gene Therapy
RP-A601 Granted Orphan Drug and Fast Track Designations for Rare Cardiomyopathy
source: pixabay.com

RP-A601 Granted Orphan Drug and Fast Track Designations for Rare Cardiomyopathy

  Gene therapy has the potential to improve outcomes among individuals across various disease spectrums. In the case of clinical-stage biotechnology company Rocket Pharmaceuticals, the company is working to develop…

Continue Reading RP-A601 Granted Orphan Drug and Fast Track Designations for Rare Cardiomyopathy